According to a 24/7 Wall Street report, seven ASCO stocks enjoyed an uptick after news from the American Society of Clinical Oncology's annual meeting (ASCO) that took place in Chicago. This meeting is said to be a catalyst for many companies each year, either sending them higher or lower.
The report highlighted a few companies making the biggest moves following the annual meeting. They explained why the stock is moving, recent trading history, consensus analyst price target and a 52-week trading range.
Loxo Oncology shares made a huge jump following an ASCO update on Saturday. The company announced interim clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase fusions, the article said. Other headliners included Puma Biotechnology Inc., Bluebird Bio Inc., TG Therapeutics Inc., Incyte Corp. and more.
Read the full story